Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04198727 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of the Impact of DPD Activity on the Efficacy of Capecitabine

Study acronym: DPDMAX
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 2, 2026 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jan 2026 to Sep 2026v10
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 5 of 5 sites
    v9
  3. Phase: Not applicable to Phase 2
    • Primary completion date: Oct 2024 to Jan 2026
    • Study completion date: Apr 2026 to Jul 2030
    v8
  4. Primary completion date: Oct 2023 to Oct 2024
    • Study completion date: Apr 2025 to Apr 2026
    v7
  5. 2 versions Re-verified since Oct 5, 2021, no change to tracked fieldsv5-v6
Show 3 earlier versionsHide 3 earlier versions
  1. Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 1 of 4 entries
    • Site details revised at 1 of 5 sites
    v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2020 to Jul 20, 2020
    • Site details revised at 5 of 5 sites
    v3
  3. Start date: Jan 2020 to Apr 2020
    • Primary completion date: Jul 2023 to Oct 2023
    • Study completion date: Jan 2025 to Apr 2025
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study evaluates the Impact of DihydroPyrimidine Dehydrogenase (DPD) activity on the efficacy of Capecitabine in patients with metastatic breast cancer. The DPD phenotype before the initiation of treatment will be assess and then the patient will be follow up during the treatment with Capecitabine up to 24 month.
Trial Details
NCT Number NCT04198727
Lead Sponsor Centre Antoine Lacassagne
Collaborators: Cerbaliance
Conditions
(from sponsor)		 Breast Neoplasm Malignant Female
Enrollment 155 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov